Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

A viral Facebook post claims that Pfizer has recently released a long list of side effects to its COVID-19 vaccine. “PFIZER ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.